Application of ANGPTL4 gene in preparation of medicine for treating pulmonary arterial hypertension
By inhibiting the expression of the ANGPTL4 gene, new drugs for pulmonary hypertension have been developed, which has solved the problem that existing drugs for treating pulmonary hypertension cannot cure diseases, and has significantly improved the symptoms and prognosis of pulmonary hypertension.
CN118924902APending Publication Date: 2024-11-12TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Patent Information
- Application Number
- CN202411025513.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-12
Smart Images

Figure CN118924902A_ABST
Abstract
The invention relates to the technical field of biological medicine. The invention provides an application of an ANGPTL4 gene in preparation of a medicine for treating pulmonary arterial hypertension, and a reagent capable of knocking out or silencing the ANGPTL4 gene. Hypoxic pulmonary hypertension can be improved and pulmonary artery remodeling can be relieved by inhibiting expression of the ANGPTL4 gene; oxidative damage and proliferation of pulmonary artery smooth muscle cells under pulmonary hypertension are reduced; and pulmonary artery smooth muscle cell mitochondrial dysfunction can be treated. A new direction is provided for improving the treatment effect and the prognosis effect of the hypoxic pulmonary hypertension patient.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Cited By
Use of a gtse1 inhibitor in the manufacture of a medicament for treating hypoxic pulmonary hypertension
CN122701723A
